A Vancouver-based research team led by Canada’s most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enough, a daily regimen of the non-prescription NSAID (nonsteroidal anti-inflammatory drug) ibuprofen can prevent the onset of Alzheimer’s disease.
This means that by taking an over-the-counter medication, people can ward off a disease that, according to Alzheimer’s Disease International’s World Alzheimer Report 2016, affects an estimated 47 million people worldwide, costs health care systems worldwide more than US$818 billion  per year and is the fifth leading cause of death in those aged 65 or older.
The Alzheimer’s Association estimates that there are more than 5 million cases in the United States alone, with a new case being identified every 66 seconds. The annual cost to the country in 2017 is estimated have been US$259 billion, with that figure predicted to potentially rise to US$1.1 trillion  by 2050.
Dr. McGeer, who is President and CEO of Vancouver-based Aurin Biotech, and his wife, Dr. Edith McGeer, are among the most cited neuroscientists in the world. Their laboratory is world-renowned for their 30 years of work in neuroinflammation and neurodegenerative diseases, particularly Alzheimer’s disease. A paper detailing Dr. McGeer’s most recent discoveries has been published in the prestigious Journal of Alzheimer’s Disease.
In 2016, Dr. McGeer and his team announced that they had developed a simple saliva test that can diagnose Alzheimer’s disease, as well as predict its future onset. The test is based on measuring the concentration of the peptide amyloid-beta protein 42 (Abeta 42) secreted in saliva. In most individuals, the rate of Abeta 42 production is almost exactly the same regardless of sex or age. However, if that rate of production is two to three times higher, those individuals are destined to develop Alzheimer’s disease. That is because Abeta 42 is a relatively insoluble material, and although it is made everywhere in the body, deposits of it occur only in the brain, causing neuroinflammation, which destroys neurons in the brains of people with Alzheimer’s disease.
Contrary to the widely held belief that Abeta 42 is made only in the brain, Dr. McGeer’s team demonstrated that the peptide is made in all organs of the body and is secreted in saliva from the submandibular gland. As a result, with as little as one teaspoon of saliva, it is possible to predict whether an individual is destined to develop Alzheimer’s disease. This gives them an opportunity to begin taking early preventive measures such as consuming non-prescription non-steroidal drugs (NSAIDs) such as ibuprofen.
“What we’ve learned through our research is that people who are at risk of developing Alzheimer’s exhibit the same elevated Abeta 42 levels as people who already have it; moreover, they exhibit those elevated levels throughout their lifetime so, theoretically, they could get tested anytime,” says Dr. McGeer. “Knowing that the prevalence of clinical Alzheimer’s Disease commences at age 65, we recommend that people get tested ten years before, at age 55, when the onset of Alzheimer’s would typically begin. If they exhibit elevated Abeta 42 levels then, that is the time to begin taking daily ibuprofen to ward off the disease.
“Unfortunately, most clinical trials to date have focused on patients whose cognitive deficits are already mild to severe, and when the therapeutic opportunities in this late stage of the disease are minimal. Consequently, every therapeutic trial has failed to arrest the disease’s progression. Our discovery is a game changer. We now have a simple test that can indicate if a person is fated to develop Alzheimer’s disease long before it begins to develop. Individuals can prevent that from happening through a simple solution that requires no prescription or visit to a doctor. This is a true breakthrough since it points in a direction where AD can eventually be eliminated.”
The Latest on: Alzheimer’s disease
via Google News
The Latest on: Alzheimer’s disease
- New Study Reveals Half of NJ residents Diagnosed with Alzheimer's Disease Do Not Receive Referrals to Support Services on December 17, 2018 at 1:47 pm
ROSELAND – A recent survey conducted by Fairleigh Dickinson University’s PublicMind on behalf of Alzheimer’s New Jersey® found that an overwhelming majority of New Jersey residents with memory loss co... […]
- Mouse Study Backs Idea That Alzheimer's May Be Transmitted on December 17, 2018 at 1:04 pm
AD is the most common cause of dementia among older adults. It is the sixth leading cause of death in the U.S. and the fifth leading cause of death for those ages ≥65. It is also the most expensive di... […]
- Rick Scott, Florida Department of Health Send $4.8 Million to Projects Across Florida Fighting Alzheimer’s on December 17, 2018 at 12:04 pm
On Monday, outgoing Gov. Rick Scott and the Florida Department of Health announced 30 grants to projects across Florida helping in the fight against Alzheimer’s Disease. The funds totaling $4.8 ... […]
- Alzheimer’s disease is the sixth leading cause of death in the United States: Letter to the Editor on December 17, 2018 at 10:31 am
I’ve been an Alzheimer’s researcher for almost 50 years, but I’m also a son who recently lost his mother to this dreadful disease. Alzheimer’s disease is the sixth leading cause of death in the United ... […]
- Neurons with good housekeeping are protected from Alzheimer's on December 17, 2018 at 8:03 am
Some neurons in the brain protect themselves from Alzheimer's with a cellular cleaning system that sweeps away toxic proteins associated with the disease, according to a new study from Columbia ... […]
- Dementia, Alzheimer's linked to stroke deaths on December 17, 2018 at 8:03 am
Dec. 17 (UPI) --Researchers in Sweden have tied deaths from ischemic stroke, or IS, to dementia and Alzheimer's disease. The research, published Friday in Current Alzheimer Research, reveals that of t... […]
- How neurons fend off Alzheimer’s with a cellular broom that clears the toxic tau protein on December 17, 2018 at 7:00 am
The Columbia team discovered in its research that harmful tau accumulates primarily in a subset of brain cells called excitatory neurons, which other researchers had previously noted are particularly ... […]
- Neurotrope Announces Publication of Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease in the Journal of Alzheimer's Disease on December 17, 2018 at 6:08 am
Publication Highlights Bryostatin's Neurorestorative Potential in the Most Challenging-to-treat and Underserved AD Patient Population 15 out of 16 Patients (94%) in the 20 μg Bryostatin-1, Non ... […]
- Eli Lilly Moving From One End Of The Spectrum To The Other For Alzheimer's Treatment on December 17, 2018 at 5:54 am
Recently, Eli Lilly (LLY) announced that it had formed a partnership deal for $2 billion to get its hands on an experimental drug for treatment of Alzheimer's disease. This deal marks for a major ... […]
via Bing News